News and Trends 24 May 2017 French Biotech Enters New Agreement to Advance its IBD Immunotherapy OSE Immunotherapeutics has teamed up with Selexis in a new license agreement to support the development of its IL-7 antagonist for the treatment of IBD. In the end of last year, French OSE Immunotherapeutics joined forces with Servier to develop and commercialize its interleukin-7 antagonist (Effi-7) in a deal that could earn the biotech up […] May 24, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
Interview 18 May 2017 #Live# Labiotech Hangout: Join our first webcast on anti-aging therapies! As we grow as a company, our content is growing too! Hang out with us and anti-aging VC managing partner, James Peyer, online next week. Join Now! We can’t wait for an event to produce videos for our readers, and we realized we don’t have to! Next week, we’re trying out a new feature and bringing additional […] May 18, 2017 - 1 minutemin - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 17 May 2017 Danish Biotech Targeting Ion Channels Completes Private Placement The biotech company Saniona has announced the issue of new shares to Swedish and international investors, raising a total of €3.6M. Saniona, a Danish biotech listed on the Nasdaq First North Premier, just completed a private placement that raised €3.6M (SEK 35M) before issue costs. The funds are intended to provide the company with more flexibility […] May 17, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 17 May 2017 A Spanish Biosimilar of Amgen’s Blockbuster gets Ready for EU Approval Cinfa Biotech announced trial results for a biosimilar of Amgen’s Neulasta, a multi-billion blockbuster to treat chemotherapy-induced neutropenia. Cinfa Biotech is a Spanish company specialized in developing biosimilars. The biotech has announced positive results from the second clinical trial evaluating a biosimilar version of Neulasta (pegfilgrastim), Amgen’s second top-selling drug. It brought the big pharma €4.2Bn in […] May 17, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 16 May 2017 Berlin Biotech Advances its Cancer Drug in a New Trial with Keytruda Noxxon Pharma has teamed up with the NCT in Heidelberg to conduct a Phase I/II trial combining its lead NOX-A12 with checkpoint inhibitor Keytruda. Based in Berlin, Noxxon is yet another biotech looking to bolster the success of checkpoint inhibitors by combining them with its ‘next-generation’ immuno-oncology candidates. The company partnered up with Merck & Co. […] May 16, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 15 May 2017 German Biotech Clears Phase I with New Gene Therapy for Glaucoma Isarna Therapeutics showed off positive Phase I data for its lead compound ISTH0036 in patients with Glaucoma at the ARVO meeting last week. Isarna Therapeutics from Munich is developing TGF-β specific antisense RNA therapeutics to treat ophthalmic and fibrotic diseases and cancer. Now the company has cleared its first Phase I trial for its lead candidate ISTH0036 in […] May 15, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 15 May 2017 How to Save Time and Money when Recruiting in the Life Sciences The right hiring choice can bring huge benefits to the growth of a life sciences company. How can you make the best decision while saving time and money? In Europe, a bad hire costs employers an average of almost €60,000, starting with a minimum of €6,000 that rapidly escalates with the seniority of the role […] May 15, 2017 - 4 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Interview 15 May 2017 Meet the CEO developing the Next Generation of Antibody Therapeutics Crescendo Biologics has positioned itself as the successor of Cambridge Antibody Technology and a new rival to Morphosys. We interviewed CEO Peter Pack. Peter Pack started working in life science 25 years ago — “quite a long time ago,” he laughs. “I’m an old guy now.” Now the CEO of Crescendo Biologics, whose Humabody platform […] May 15, 2017 - 8 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 13 May 2017 Visualizing the Microbiome through Handmade Embroidery Rebecca Harris is a British artist that uses handmade embroidery to visually communicate the huge diversity of microbes that form part of our bodies. Trillions of microbes live on us and inside us. “Microbes are essential for our well-being and development. The microbes stimulate and develop the immune response, and they detoxify harmful carcinogenic compounds in our […] May 13, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 12 May 2017 German Biotech Raises €15M to Treat Heart Failure with Non-coding RNA Cardior Pharmaceuticals will use the funds to develop an innovative technology based on non-coding RNAs involved in cardiac remodeling. Founded less than a year ago, Cardior Pharmaceuticals is dedicated to developing a novel technology to predict and treat heart failure. In such a short timeframe, the German biotech has managed to attract some of the best […] May 12, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 12 May 2017 Resurrected Proteins could be New Weapon against Crop Viruses Researchers from Spain have succeeded in expressing a 4 billion year-old enzyme in a present-day E. coli. It’s similar enough to the modern version to work, but different enough to dupe viruses. A new way to create virus resistance in crops? In a lab at the University of Granada, Spain, that specializes in reconstructing ancient gene sequences, researchers have […] May 12, 2017 - 3 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 12 May 2017 UPDATE: Italian Pharma receives €11M for Parkinson’s Drug Approval UPDATE (12/05/2017): Newron has received €11.3M as a milestone payment for the approval from its partner, Zambon, which has the rights to commercialise Xadago globally. Originally published on 21/04/2017 Newron, an Italian biotech focused on CNS diseases, is on a roll. The latest win? FDA approval of its Parkinson’s drug, Xadago. Just in time for World […] May 12, 2017 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email